Dubois-Presle N, Lapicque F, Maurice M H, Fournel-Gigleux S, Magdalou J, Abiteboul M, Siest G, Netter P
Laboratoire de Pharmacologie, URA CNRS 1288, Faculté de Médecine, Nancy, France.
Mol Pharmacol. 1995 Mar;47(3):647-53.
Many carboxylic acid-containing drugs undergo conjugation with D-glucuronic acid in humans, leading to the formation of acyl glucuronides, which are excreted into urine. However, these metabolites can be hydrolyzed back to the parent aglycon; this reaction can be accelerated by human serum albumin (HSA). Although this phenomenon of interaction between the acyl glucuronide and HSA has been described for various drugs, the kinetics of the protein have not been characterized. The aim of this study was to investigate the HSA-mediated mechanism involved in the in vitro hydrolysis by albumin of the acyl glucuronides of (R)- and (S)-ketoprofen (a nonsteroidal anti-inflammatory drug), as model compounds. The conjugates of both ketoprofen enantiomers were incubated, separately or together, with increasing concentrations of albumin (14.5-145 microM) at pH 7.4 and 37 degrees. The reaction followed Michaelis-Menten kinetics and was stereoselective; the (R)-ketoprofen glucuronide was a better substrate than the S-conjugate. To identify the HSA domain involved in the hydrolysis reaction, specific probes of HSA binding sites were used as potential inhibitors. These probes, added at an equimolar probe/glucuronide ratio (145 microM), slightly decreased the hydrolysis (by up to 30%). They affected the reversible binding of (R)-ketoprofen glucuronide to HSA, as shown by CD studies. Because iodoacetic acid did not modify the single free cysteine residue on HSA, this amino acid residue cannot be the reactive one. In addition, the chemical modification of a single tyrosine residue (probably Tyr-411) on HSA by diisopropyl fluorophosphate significantly but weakly affected the hydrolysis of (R)-ketoprofen glucuronide, suggesting that this residue also is not involved in the catalysis. In contrast, the R-conjugate was not bound to modified albumin, as revealed in CD experiments. These results support the existence of distinct sites on HSA for reversible binding and hydrolysis of (R)-ketoprofen glucuronide.
许多含羧酸的药物在人体内会与D - 葡萄糖醛酸结合,生成酰基葡萄糖醛酸苷,这些产物会随尿液排出。然而,这些代谢产物可能会水解回母体苷元;人血清白蛋白(HSA)可加速此反应。尽管已经针对多种药物描述了酰基葡萄糖醛酸苷与HSA之间的这种相互作用现象,但尚未对该蛋白的动力学进行表征。本研究的目的是研究HSA介导的体外水解机制,以(R)-和(S)-酮洛芬(一种非甾体抗炎药)的酰基葡萄糖醛酸苷作为模型化合物,由白蛋白进行水解。将两种酮洛芬对映体的缀合物分别或一起与浓度不断增加的白蛋白(14.5 - 145 microM)在pH 7.4和37℃下孵育。该反应遵循米氏动力学且具有立体选择性;(R)-酮洛芬葡萄糖醛酸苷是比S - 缀合物更好的底物。为了鉴定参与水解反应的HSA结构域,使用HSA结合位点的特异性探针作为潜在抑制剂。这些探针以等摩尔探针/葡萄糖醛酸苷比例(145 microM)添加,可使水解略有降低(最多降低30%)。如圆二色性(CD)研究所示,它们影响了(R)-酮洛芬葡萄糖醛酸苷与HSA的可逆结合。由于碘乙酸不会修饰HSA上的单个游离半胱氨酸残基,因此该氨基酸残基不可能是反应性残基。此外,二异丙基氟磷酸对HSA上的单个酪氨酸残基(可能是Tyr - 411)进行化学修饰,对(R)-酮洛芬葡萄糖醛酸苷的水解有显著但微弱的影响,表明该残基也不参与催化作用。相反,如CD实验所示,R - 缀合物不与修饰后的白蛋白结合。这些结果支持HSA上存在不同的位点用于(R)-酮洛芬葡萄糖醛酸苷的可逆结合和水解。